CellCarta's cell counting solutions cover a broad range of immune cell populations,including CD4/CD8 T-cells,CD19 B-cells,CD16/CD56 NK cells,CD34+ progenitor cells,monocytic and granulocytic MDSC,CAR T-cells,and residual leukocytes in leukoreduced blood products. Panel selection is guided by your study's therapeutic target and endpoint requirements.
"},{"faq_question":"Are your TBNK assays validated for regulatory submissions?","faq_answer":"Yes. Our standard TBNK panel carries IVD status,making it suitable for use in regulatory submissions when used according to specifications. Additionally,our standard TBNK and TBNK + CD20 panels are validated for secondary endpoint studies,and can be an invaluable tool for patient stratification,and multi-center trial requirements.
"},{"faq_question":"Can you support multi-site clinical trials?","faq_answer":"Yes. All cell counting solutions are cross-validated across CellCarta's global laboratory network. Panels are validated with the same level of rigor at each site,ensuring inter-site reproducibility and consistent data quality for multi-center studies.
"},{"faq_question":"How soon can cell enumeration results be reported?","faq_answer":"Our team will work with you to discuss timelines and ensure all results are delivered on time,preventing unnecessary delays in trial progress. For example,our standardized TBNK workflows support official reporting within five days,providing the turnaround speed required for time-sensitive clinical decisions.
"}]}#-supreme-cellcarta-service-blocks-7-712{blocks-data:[{"image":"https://cellcarta.com/wp-content/uploads/2026/08/CellCarta_-44-1-scaled.jpg","image_alt":"Cell proliferation assay laboratory scientist","title":"Cell Proliferation","description":"Assess immune cell division and cycling to evaluate treatment response and immune activation.","button_text":"Discover","button_url":"/capabilities/immune-monitoring/cell-proliferation-assays/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/06/Basophil-Activation-Test-22.jpg","image_alt":"Basophil activation test laboratory scientist","title":"Basophil Activation Test","description":"Measure basophil degranulation to assess allergic and hypersensitivity immune responses.","button_text":"Discover","button_url":"/capabilities/immune-monitoring/basophil-activation-test/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/06/CellEngine-Software-80.jpg","image_alt":"CellEngine software flow cytometry data visualization","title":"CellEngine Software","description":"Advanced flow cytometry analysis and data visualization with incredible speed.","button_text":"Discover","button_url":"/clinical-trial-services/ai-data-analytics/cellengine-cytometry-software/","button_target":"_self"}]}#-supreme-cellcarta-tab-content-4-712{oxy-supreme-cellcarta-tab-content-content-heading-tag:h3;oxy-supreme-cellcarta-tab-content-content-heading-size:default;oxy-supreme-cellcarta-tab-content-content-body-size:default;tabs-data:[{"tab_title":"Validated TBNK","content_title":"","content_body":"Our TBNK panels,cross-validated at all our global sites,allow for precise enumeration of T-cells,B-cells,and NK cells. Our off-the-shelf (OTS) offerings include:
\nRead our brochure to learn more.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Validated-TBNK-tab-123.jpg","image_alt":"CellCarta scientist running TBNK flow cytometry panel"},{"tab_title":"CD34+ Cells","content_title":"","content_body":"Our workflow easily enumerates CD34+ progenitor cells in whole blood following mobilization using hematopoietic growth factors.
\nOur protocols follow guidelines established by ISHAGE (International Society of Hematotherapy and Graft Engineering),providing consistent,regulatory-ready results for transplant and cell therapy programs.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/CD34-Cells-tab-116.jpg","image_alt":"CD34+ progenitor cell enumeration in whole blood"},{"tab_title":"Residual Leukocytes","content_title":"","content_body":"We can enumerate residual leukocytes for quality control of leukoreduced blood products. Our cell counting solutions provide a reliable,validated approach to confirming therapeutic efficacy,supporting product release and regulatory documentation.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Residual-Leukocytes-tab-55.jpg","image_alt":"Residual leukocyte enumeration in leukoreduced blood products"},{"tab_title":"Immunotherapies","content_title":"","content_body":"We can support immunotherapy programs with cell counting solutions designed for the demands of complex clinical endpoints.
\nCellCarta enumerates CAR T-cells and myeloid-derived suppressor cells (MDSC) as part of a broader immune monitoring strategy,providing the absolute counts needed to track therapeutic activity and inform patient management decisions.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Immunotherapies-tab-128.jpg","image_alt":"Immunotherapy cell counting for CAR T and MDSC"}]}